Skip to main
ELMD

Electromed (ELMD) Stock Forecast & Price Target

Electromed (ELMD) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Electromed Inc. demonstrated robust financial growth, with homecare revenue increasing by 14.8% to $14.1 million, driven by enhanced sales representative productivity and strong demand generation. The company has successfully expanded its footprint in the domestic homecare sector while making inroads into acute care and international markets, highlighted by a 41% rise in distributor sales and a remarkable 52% growth in hospital sales. Despite an increase of 17.2% in SG&A expenses due to strategic investments in sales and marketing, these efforts are aligned with Electromed's commitment to fostering long-term growth.

Bears say

Electromed Inc faces significant challenges that contribute to a negative outlook on its stock, including margin compression, which may pressure profitability, and competitive headwinds that threaten market position. Additionally, reduced productivity among the sales force could hinder revenue growth, further exacerbating financial performance issues. Delays in the anticipated contributions from Pain Management and Wound Care segments may also negatively impact overall growth rates and future margins.

Electromed (ELMD) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Electromed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Electromed (ELMD) Forecast

Analysts have given Electromed (ELMD) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Electromed (ELMD) has a Strong Buy consensus rating as of Jan 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Electromed (ELMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.